Chemed (CHE) Q1 2026: VITAS Admissions Up 6.9% as Roto-Rooter Paid Leads Hit 53%
Chemed’s Q1 2026 results reveal VITAS outpacing growth targets and Roto-Rooter navigating digital lead cost inflation. The company’s raised guidance reflects hospice momentum, but persistent marketing headwinds and operational transition at Roto-Rooter temper overall margin optimism. Investors should weigh VITAS’s durable growth signals against ongoing digital acquisition cost pressure and evolving regulatory scrutiny.
Summary
- Hospice Outperformance: VITAS admissions and cap cushion gains exceeded expectations, prompting guidance raise.
- Lead Generation Shift: Roto-Rooter paid leads now comprise more than half of total, raising cost base.
- Margin Pressure Persists: Marketing spend and digital channel volatility remain key watchpoints for Roto-Rooter profitability.
Performance Analysis
Chemed’s Q1 2026 results highlight a tale of two segments: VITAS, hospice and palliative care, delivered strong revenue and margin performance, while Roto-Rooter, plumbing and drain services, contended with increased marketing spend and weather-driven disruptions. VITAS net revenue grew 3.1%, driven by higher days of care and a Medicare reimbursement rate increase, even as acuity mix and Medicare cap headwinds trimmed topline gains. Admissions climbed 6.9% year-over-year, with Florida’s cap position adding $32.5 million in cushion and no anticipated cap limitations for the fiscal year. Adjusted EBITDA margin for VITAS excluding Medicare cap reached 16.8%.
Roto-Rooter’s core residential and commercial services saw their first revenue uptick since 2022, but overall profitability was pressured by paid digital leads rising to 53.4% of total (up from 46.5%), requiring nearly $3 million more in marketing spend. Weather disruptions shaved $3-4 million off top-line potential, and centralized billing transitions weighed on water restoration revenue per job. Despite these challenges, Roto-Rooter executed two franchise acquisitions serving 3.3 million people, expected to add $5-5.5 million in incremental revenue for the remainder of 2026, though with initially lower margins.
- Admissions Surge: VITAS admissions rose 6.9%, outpacing expectations and supporting upward guidance revision.
- Digital Marketing Cost Inflation: Roto-Rooter’s marketing spend increased by $3 million, with paid leads now dominant.
- Operational Disruption: Weather events and billing centralization created near-term margin and revenue headwinds in Roto-Rooter.
While VITAS’s operational execution underpinned upward guidance, Roto-Rooter’s margin compression and digital marketing dependency remain key areas for close scrutiny in coming quarters.
Executive Commentary
"VITAS performance during the quarter exceeded even the high end of our expectations... This was achieved while also keeping hospice labor costs lower than budgeted. These factors combined to allow VITAS to achieve higher than expected revenue growth and EBITDA margins while continuing to add cushion to the Medicare cap position in our Florida combined program."
Kevin McNamara, President and CEO
"The decline in adjusted EBITDA margin was mainly caused by increased internet marketing costs... The entire change in the EBITDA margin in the guidance is us adding a million dollars per quarter of marketing costs for the next three quarters."
Mike Wissman, Chief Financial Officer
Strategic Positioning
1. VITAS: Hospice Growth and Cap Management
VITAS is capitalizing on both hospital and non-hospital admissions, with Florida’s cap issue now resolved and a normalized growth trajectory. The segment’s ability to increase average daily census (ADC) while maintaining labor efficiency has supported margin expansion and a confident guidance raise.
2. Roto-Rooter: Paid Lead Economics and Franchise Acquisitions
Roto-Rooter’s business model is increasingly reliant on paid digital marketing channels, with over half of leads now purchased, reflecting a structural shift in customer acquisition. The acquisition of two major franchises expands geographic reach, but initial margins lag the broader portfolio, requiring integration and operational improvement to realize full value.
3. Margin Structure Under Pressure
Elevated marketing costs and digital channel volatility are now embedded in Roto-Rooter’s cost base, prompting a downward revision to EBITDA margin guidance. Management expects these pressures to persist, with only gradual improvement possible as digital visibility stabilizes and centralized billing matures.
4. Regulatory Scrutiny and Fraud Mitigation
VITAS faces an evolving regulatory landscape, particularly in California, where fraud enforcement and new CMS scoring systems are under discussion. Leadership is proactively engaging in comment periods and advocating for oversight that targets fraudulent operators without inhibiting legitimate providers’ access and growth.
5. Capital Allocation and Guidance Philosophy
Chemed’s decision to update full-year guidance mid-year signals management’s conviction in VITAS’s performance, while also acknowledging persistent cost headwinds at Roto-Rooter. Share repurchases and disciplined acquisition strategy remain core to capital deployment, balanced against operational reinvestment needs.
Key Considerations
This quarter’s results underscore the bifurcation between Chemed’s healthcare and home services segments. Investors should focus on the sustainability of VITAS’s growth drivers and the durability of Roto-Rooter’s digital marketing model as the company navigates a changing industry landscape.
Key Considerations:
- Hospice Demand and Cap Stability: VITAS’s strong ADC growth and Florida cap cushion position the segment for continued outperformance, but regulatory changes could alter reimbursement dynamics.
- Digital Lead Acquisition Costs: Roto-Rooter’s shift to paid digital leads exposes it to ongoing cost inflation and algorithm risk, challenging margin predictability.
- Operational Integration of Acquisitions: Recent franchise purchases offer scale but require management focus to lift margins to system averages.
- Regulatory and Fraud Enforcement Headwinds: Heightened scrutiny in the hospice sector could create compliance costs or disrupt growth, especially in high-risk markets like California.
Risks
Chemed’s outlook is tempered by several material risks: Roto-Rooter’s profitability is increasingly sensitive to digital marketing cost and algorithm changes, while ongoing regulatory scrutiny and potential changes to CMS reimbursement or scoring systems could impact VITAS’s revenue and access. Integration risk from new franchise acquisitions and persistent labor market tightness in healthcare also warrant close monitoring.
Forward Outlook
For Q2 2026, Chemed guided to:
- Continued ADC growth and margin expansion at VITAS as headcount ramps to meet demand
- Stable but pressured Roto-Rooter margins as marketing costs remain elevated
For full-year 2026, management raised guidance:
- VITAS ADC growth now 4.5% to 5.5% (up from 3.5% to 4%)
- VITAS revenue growth (ex-cap) 6.5% to 7.5%
- VITAS EBITDA margin (ex-cap) 18% to 18.5%
- Roto-Rooter revenue growth unchanged at 3% to 3.5%
- Roto-Rooter EBITDA margin revised to 21.5% to 22.5% (down from 22.5% to 23%)
- Adjusted EPS guidance raised to $24 to $24.75 (midpoint now +13% YoY)
Management highlighted:
- VITAS’s labor additions will support continued ADC growth
- Roto-Rooter’s marketing spend will remain above prior expectations as digital channel mix persists
Takeaways
Chemed’s Q1 2026 demonstrates the company’s ability to drive growth in hospice while navigating structural cost shifts in home services.
- Hospice Growth Engine: VITAS’s admissions and cap management support a raised outlook and underpin overall company earnings momentum.
- Marketing Cost Reset: Roto-Rooter’s digital lead shift is now a structural cost, compressing margins and requiring ongoing operational adaptation.
- Future Watchpoint: Monitor digital marketing cost trends and regulatory developments in hospice for signals of further guidance risk or upside.
Conclusion
Chemed’s Q1 2026 results reflect a robust recovery at VITAS and persistent marketing-driven headwinds at Roto-Rooter. While hospice momentum supports a higher full-year forecast, Roto-Rooter’s evolving digital acquisition model and regulatory uncertainty in healthcare remain critical variables for future performance.
Industry Read-Through
Chemed’s experience this quarter highlights two broader industry currents: In healthcare, the hospice sector’s growth is increasingly tied to regulatory cap management and fraud enforcement, with legitimate providers needing to navigate shifting oversight and reimbursement models. In home services, the rising cost and volatility of digital customer acquisition—driven by search algorithm changes and increased paid lead reliance—signal a new normal for service businesses dependent on online channels. Investors across both sectors should monitor the interplay of digital marketing economics, regulatory risk, and operational leverage as structural forces shaping future returns.